Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Odyssey Therapeutics Q3 2026 Results: Net Loss of $53.1M, Loss Widens

Odyssey Therapeutics is a clinical-stage biotechnology company that recently transitioned to a public entity following its IPO. The company reported 48,067,877 shares of common stock outstanding as of November 2, 2026, and continues to incur substantial net losses as it advances its lead product candidates, OD-001 and OD-002, through clinical and preclinical development.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue0.00.1
Profit before tax-53.0-35.5
Net income-53.1-35.5
EPS (diluted, $ a share)$-1.10$-7.78

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NASDAQ: ODTX. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Odyssey Therapeutics, Inc.: key numbers

Share price
$19.36Close, Nov 16
Market cap
$931M
Shares outstanding
48.07MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Odyssey Therapeutics, Inc.

All →
7:00 AM ET 8-K
Financial Results

Odyssey Therapeutics Financial Results

Odyssey Therapeutics reported third quarter 2026 financial results, ending the period with $387 million in cash and equivalents. The company highlighted clinical progress for its RIPK2 inhibitor OD-001 in ulcerative colitis and the completion of IND-enabling studies for its SLC15A4 inhibitor OD-002.

Term
Q3 2026

“Over the past several months, we have made meaningful progress across our entire pipeline, highlighted by additional analyses from the Phase 2a induction period for OD-001 demonstrating that clinical efficacy is supported by concordant biomarker and transcriptomic findings, further reinforcing previously established clinical proof of concept in patients with ulcerative colitis.”

Gary D. Glick, Ph.D., founder and chief executive officer of Odyssey Therapeutics

“We have also continued to advance the clinical development of OD-001 while completing IND-enabling studies for OD-002, our SLC15A4 inhibitor. Together with an enhanced executive leadership team and strong financial foundation, these achievements position us to execute on our clinical development strategy and drive continued progress throughout our portfolio.”

Gary D. Glick, Ph.D., founder and chief executive officer of Odyssey Therapeutics
7:01 AM ET 8-K
Clinical Trial Data

Odyssey Therapeutics Clinical Trial Data

Odyssey Therapeutics announced positive Phase 2a results for its oral RIPK2 inhibitor, OD-001, in patients with moderate-to-severe ulcerative colitis. The trial met its primary endpoint with a 27% clinical remission rate at the 20 mg BID dose at Week 12, showing significant correlation between clinical efficacy and inflammatory biomarkers.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.